Ecuador issues compulsory licence for Abbott's Kaletra

Abbott's antiretroviral Kaletra (lopinavir plus ritonavir) is facing generic competition in Ecuador after the government issued a compulsory licence, following a request from the ESKE Group, for ritonavir on 14 April. The R&D pharmaceutical industry has criticised the decision, saying it undermines the patent system.

Abbott's antiretroviral Kaletra (lopinavir plus ritonavir) is facing generic competition in Ecuador after the government issued a compulsory licence, following a request from the ESKE Group, for ritonavir on 14 April. The R&D pharmaceutical industry has criticised the decision, saying it undermines the patent system.

In addition the Indian firm Matrix has requested a second compulsory licence for the same drug, which could follow soon,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anti-infective

More from Therapeutic Category